CA-TALKDESK
Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, today launched its latest annual Talkdesk Global Contact Center Key Performance Indicator (KPI) Benchmarking report. Announced this week at Customer Contact Week Las Vegas 2024, the report measures five traditional contact center performance metrics and indicates that amid surging inbound call volumes in 2023, AI helps organizations improve speed to answer, maintain service levels, and more.
The proprietary global data—gathered from across a wide range of industries, company sizes, and locations in 2023—is designed to help contact center leaders successfully navigate industry changes, especially the implications of generative AI (GenAI) on contact center operations and CX delivery. Moreover, the report contains six months of data since Talkdesk layered GenAI across the entire contact center platform, including its flagship Talkdesk CX Cloud™ and Industry Experience Clouds.
While Talkdesk has been an AI innovator since 2018, GenAI radically changed the contact center landscape in 2023. The report will help contact center leaders compare their performance against peers and understand how they can best implement AI and GenAI solutions in order to excel in core contact center competencies.
Among the KPI benchmarks’ insight into the performance and opportunities for success in contact centers, key findings include:
As call volumes increase, KPI indicators show AI offers a path to improved speed to answer and service levels.
- Total inbound calls increased 21% to 390 million in 2023 across Talkdesk customers. In a positive outlook for rising AI usage, speed to answer improved significantly – down 13% to an average of 8.7 seconds – and service level improved slightly to 75.61%.
- While recruitment and attrition were challenges in 2023, AI-powered self-service solutions helped handle a portion of the large volumes of calls despite labor shortages. These results indicate that AI is enabling organizations to engage with customers faster.
Human agents remain critical to the contact center.
- The role of the agent is still mission-critical. With inbound call volumes reaching over 390 million and the average talk time hovering around 2 minutes and 50 seconds, the data implies human agents will likely focus on handling more complex issues and customers who would rather have a human resolve their queries than AI.
Industry-specific contact center solutions correlate with higher service levels.
- While the average service level was maintained from 2022 to 2023 (75.4% in 2022 vs. 75.6% in 2023), some industries achieved higher service levels, including retail and consumer goods (RCG) at 78.5%. Organizations that deploy industry-tailored solutions, like Talkdesk Autopilot for Retail, Banking, and Healthcare, can accelerate contact center transformation with AI. The data implies industries can better address vertical-specific CX queries due to these tailored solutions.
To explore more data findings and examples from organizations seeing success today by leveraging AI and automation tools in the contact center – including results of 90%+ service levels – download the 2024 Talkdesk Global Contact Center KPI Benchmarking Report here.
Supporting Quotes
Neville Letzerich, chief marketing officer at Talkdesk, said: “Contact center KPI benchmarking helps center managers determine best practices, critically evaluate their business, and implement changes to be more competitive. Correlations between AI adoption and traditional contact center KPI performance enables decision makers to intelligently invest in technology solutions that meet their goals and ensure they keep pace with industry standards on AI.”
Crendal Kear, senior vice president of Customer Success at Talkdesk, commented: “As contact center managers operate in a radically changing, increasingly competitive landscape, benchmarking KPI data is invaluable to understand how their center operations measure up. Our customers have different goals, but we believe that learning from the collective experience is important as it reveals opportunities to prioritize success that likely wouldn’t surface from internal reflection.”
About Talkdesk
Talkdesk® is on a mission to rid the world of bad customer experience. With our cloud-native, generative AI-powered CX platform, purpose-built industry solutions, and extensible AI offerings, we empower enterprises in the cloud and on-premises to deliver exceptional customer experiences that make them more competitive, grow revenue, reduce costs, and provide operational efficiencies. With specialized workflows and integrations delivered out of the box for our Industry Experience Clouds, Talkdesk accelerates value for our customers faster and more simply than legacy or one-size-fits-all solutions.
Partnering with enterprises globally, we deliver continuous innovation and breakthrough results. Our commitment to reliability and security, paired with our track record of delivering on promises, sets us apart in the industry. Elevate customer experiences, streamline operations, and increase revenue with Talkdesk. Companies that love their customers use Talkdesk.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603611611/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
